LVTX Overview

Acquisition Announcement: XOMA Royalty Corporation has completed its acquisition of LAVA Therapeutics N.V., with LAVA shareholders receiving $1.04 in cash per share and a contingent value right (CVR) for potential future payments.

Strategic Benefits: The acquisition is expected to enhance XOMA's portfolio by adding two early-stage bispecific antibodies developed in collaboration with major oncology partners, potentially driving significant value for both XOMA and LAVA shareholders.

Tender Offer Details: The tender offer for LAVA shares concluded with approximately 91.1% of outstanding shares validly tendered, leading to a corporate reorganization that resulted in XOMA acquiring 100% of LAVA.

Future Outlook: XOMA Royalty emphasizes the potential for future economic benefits from LAVA's partnered and unpartnered programs, while also cautioning that forward-looking statements regarding these benefits are subject to various risks and uncertainties.

Tender Offer Success: LAVA Therapeutics announced that approximately 87% of its outstanding common shares were validly tendered in the offer from XOMA Royalty, satisfying the minimum tender condition for the acquisition.

Subsequent Offering Period: A subsequent offering period has begun for LAVA shareholders who have not yet tendered their shares, which will end on November 20, 2025, with shares expected to be suspended from trading on Nasdaq shortly thereafter.

Voluntary Delisting: LAVA has notified Nasdaq of its intention to voluntarily delist its common shares, contingent upon the completion of the acquisition by XOMA Royalty.

Forward-Looking Statements: The press release includes cautionary notes regarding forward-looking statements, highlighting various risks and uncertainties that could affect the completion of the tender offer and LAVA's business operations.

Investigation Announcement: The Ademi Firm is investigating Lava (Nasdaq: LVTX) for potential breaches of fiduciary duty related to its transaction with XOMA Royalty, including concerns over the terms of the deal and the conduct of Lava's board of directors.

Transaction Details: Under the amended agreement, Lava shareholders will receive a reduced initial cash amount of $1.04 per share and a contingent value right, while the minimum net-cash closing condition has been lowered from $31.5 million to $24.5 million, raising concerns about the limitations on competing bids.

Amendment Details: LAVA Therapeutics and XOMA Royalty Corporation have amended their share purchase agreement, reducing the initial cash amount per share to $1.04 and updating the contingent value rights (CVR) terms, including a new right to receive additional cash based on potential liabilities.

Extended Offer Timeline: The tender offer for LAVA shares has been extended to November 12, 2025, with the acquisition expected to close in the fourth quarter of 2025, pending customary closing conditions and shareholder approvals.

Extraordinary General Meeting: LAVA will reconvene its Extraordinary General Meeting of Shareholders on November 7, 2025, to approve resolutions related to the transactions with XOMA Royalty, which were previously scheduled for September 30, 2025.

Forward-Looking Statements: Both companies have issued cautionary notes regarding forward-looking statements, highlighting potential risks and uncertainties that could affect the completion and benefits of the transactions.

Tender Offer Extension: XOMA Royalty Corporation has extended its tender offer for LAVA Therapeutics' shares until October 17, 2025, allowing shareholders to receive cash and a contingent value right based on future proceeds from LAVA's partnered and unpartnered assets.

Acquisition Process: The acquisition is expected to close in Q4 2025, contingent on certain conditions including the tender of at least 80% of LAVA's shares and the adoption of specific resolutions by LAVA's shareholders.

Tender Offer Extension: XOMA Royalty and LAVA Therapeutics have extended the tender offer expiration to October 17, 2025, at 11:59 p.m. ET.

Acquisition Details: The offer includes a cash payment and a non-transferable contingent value right (CVR) for 75% of net proceeds from partnered assets and any out-licensed or sold unpartnered programs, with the acquisition expected to close in Q4 2025.